ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Fujifilm's Avigan hopes hit after Japan puts COVID drug on hold

Health ministry panel says efficacy difficult to judge from available data

Japan's health ministry has put off approval of Fujifilm's anti-influenza drug Avigan for use in treating COVID-19. The company's shares fell sharply on the news on Dec. 22. (Photo byTakaki Kashiwabara)

TOKYO -- Japan's Fujifilm Holdings said it was "extremely disappointed," after government officials deferred approval of its Avigan treatment for COVID-19, setting back the company's global ambitions for the drug.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more